{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:44:40Z","timestamp":1770223480448,"version":"3.49.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R03-AR065157"],"award-info":[{"award-number":["R03-AR065157"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI076423"],"award-info":[{"award-number":["R01-AI076423"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01-DA031064"],"award-info":[{"award-number":["R01-DA031064"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01-MH65151"],"award-info":[{"award-number":["R01-MH65151"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00156","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T04:26:07Z","timestamp":1517545567000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Kallikrein\u2013Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation"],"prefix":"10.3389","volume":"9","author":[{"given":"Alecia","family":"Seliga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Hweemoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole C.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Zuluaga-Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Didukh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Persidsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghava","family":"Potula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Gallucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)00058-4","article-title":"Bioregulation of kinins: kallikreins, kininogens, and kininases","volume":"44","author":"Bhoola","year":"1992","journal-title":"Pharmacol Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1254\/jphs.SRJ05001X","article-title":"The kallikrein-kinin system: current and future pharmacological targets","volume":"99","author":"Moreau","year":"2005","journal-title":"J Pharmacol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/ki.2008.647","article-title":"The kallikrein-kinin system in health and in diseases of the kidney","volume":"75","author":"Kakoki","year":"2009","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00018-008-8024-3","article-title":"Kallikrein-related peptidases","volume":"65","author":"Lundwall","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrd1522","article-title":"Bradykinin receptor ligands: therapeutic perspectives","volume":"3","author":"Marceau","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"B6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: renin-angiotensin-aldosterone system alterations","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ Res"},{"key":"B7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(25)06820-6","article-title":"Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors","volume":"47","author":"Linz","year":"1995","journal-title":"Pharmacol Rev"},{"key":"B8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-3565(25)28878-4","article-title":"Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme)","volume":"177","author":"Yang","year":"1971","journal-title":"J Pharmacol Exp Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus \u2013 results from LUMINA (LIX): a multiethnic US cohort","volume":"47","author":"Duran-Barragan","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S684","DOI":"10.1097\/00004872-198812040-00215","article-title":"Effect of captopril on murine systemic lupus erythematosus disease","volume":"6","author":"Herlitz","year":"1988","journal-title":"J Hypertens Suppl"},{"key":"B12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/gene.2009.7","article-title":"The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis","volume":"10","author":"Li","year":"2009","journal-title":"Genes Immun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"73s9","DOI":"10.1126\/scitranslmed.3002138","article-title":"Dissecting the immune cell mayhem that drives lupus pathogenesis","volume":"3","author":"Craft","year":"2011","journal-title":"Sci Transl Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1002\/eji.200737815","article-title":"Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms","volume":"37","author":"Barrat","year":"2007","journal-title":"Eur J Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard.2010.135186","article-title":"Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.rdc.2009.12.008","article-title":"Interferon-alpha: a therapeutic target in systemic lupus erythematosus","volume":"36","author":"Crow","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"B17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/ar1888","article-title":"Targeting toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus","volume":"8","author":"Lenert","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1600-065X.2008.00630.x","article-title":"Development of TLR inhibitors for the treatment of autoimmune diseases","volume":"223","author":"Barrat","year":"2008","journal-title":"Immunol Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1172\/JCI36728","article-title":"Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans","volume":"119","author":"Liu","year":"2009","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/IJWH.S28034","article-title":"Understanding lupus nephritis: diagnosis, management, and treatment options","volume":"4","author":"Mok","year":"2012","journal-title":"Int J Womens Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4049\/jimmunol.1101686","article-title":"Myeloid dendritic cells from B6.NZM Sle1\/Sle2\/Sle3 lupus-prone mice express an IFN signature that precedes disease onset","volume":"189","author":"Sriram","year":"2012","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12016-009-8192-4","article-title":"The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies","volume":"40","author":"Weckerle","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.4049\/jimmunol.179.10.6446","article-title":"IL-4 suppresses dendritic cell response to type I interferons","volume":"179","author":"Sriram","year":"2007","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e87668","DOI":"10.1371\/journal.pone.0087668","article-title":"IL-4 suppresses the responses to TLR7 and TLR9 stimulation and increases the permissiveness to retroviral infection of murine conventional dendritic cells","volume":"9","author":"Sriram","year":"2014","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4049\/jimmunol.1500152","article-title":"STAT2 is required for TLR-induced murine dendritic cell activation and cross-presentation","volume":"197","author":"Xu","year":"2016","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.4049\/jimmunol.170.11.5349","article-title":"Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization","volume":"170","author":"Aliberti","year":"2003","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1046\/j.1365-2249.2000.01323.x","article-title":"Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals","volume":"121","author":"Odaka","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"36922","DOI":"10.1074\/jbc.M112.402958","article-title":"Prostaglandin E2-induced IL-23p19 subunit is regulated by cAMP-responsive element-binding protein and C\/AATT enhancer-binding protein beta in bone marrow-derived dendritic cells","volume":"287","author":"Kocieda","year":"2012","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/j.1537-2995.2006.01033.x","article-title":"A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers","volume":"46","author":"Dietz","year":"2006","journal-title":"Transfusion"},{"key":"B32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"948364","DOI":"10.1155\/2010\/948364","article-title":"Interferon alpha in systemic lupus erythematosus","volume":"2010","author":"Niewold","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1016\/j.jmb.2013.09.041","article-title":"The antiviral activities of ISG15","volume":"425","author":"Morales","year":"2013","journal-title":"J Mol Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1182\/blood.V96.9.3029","article-title":"Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures","volume":"96","author":"Brasel","year":"2000","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0022-3565(24)39065-2","article-title":"Metabolism of bradykinin in vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite","volume":"294","author":"Murphey","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.clim.2010.03.008","article-title":"Effect of combining ACE inhibitor and statin in lupus-prone mice","volume":"136","author":"Shimazu","year":"2010","journal-title":"Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.intimp.2015.05.052","article-title":"Captopril inhibits maturation of dendritic cells and maintains their tolerogenic property in atherosclerotic rats","volume":"28","author":"Li","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/art.22445","article-title":"Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression","volume":"56","author":"Brechter","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bcp.2015.07.034","article-title":"Enhanced Ca(2+) response and stimulation of prostaglandin release by the bradykinin B2 receptor in human retinal pigment epithelial cells primed with proinflammatory cytokines","volume":"97","author":"Catalioto","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/art.38082","article-title":"Contrasting mechanisms of interferon-alpha inhibition by intravenous immunoglobulin after induction by immune complexes versus toll-like receptor agonists","volume":"65","author":"Wiedeman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1113\/expphysiol.2004.028464","article-title":"Kallikrein-kinin in stroke, cardiovascular and renal disease","volume":"90","author":"Chao","year":"2005","journal-title":"Exp Physiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2174\/157016310793180611","article-title":"Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis","volume":"7","author":"Hebb","year":"2010","journal-title":"Curr Drug Discov Technol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1172\/JCI38786","article-title":"Kallikreins and lupus nephritis","volume":"119","author":"Ponticelli","year":"2009","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1515\/BC.2010.056","article-title":"Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies","volume":"391","author":"Avgeris","year":"2010","journal-title":"Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.21571","article-title":"The type I interferon system in systemic lupus erythematosus","volume":"54","author":"Ronnblom","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/sji.12330","article-title":"Systemic lupus erythematosus \u2013 a disease with a dysregulated type I interferon system","volume":"82","author":"Hagberg","year":"2015","journal-title":"Scand J Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"CD009333","DOI":"10.1002\/14651858.CD009333.pub3","article-title":"Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis","volume":"11","author":"La Mantia","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cld.2016.06.002","article-title":"Interferon treatment for hepatitis B","volume":"20","author":"Konerman","year":"2016","journal-title":"Clin Liver Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-immunol-032713-120156","article-title":"Innate immune sensing and signaling of cytosolic nucleic acids","volume":"32","author":"Wu","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2017.03.008","article-title":"Regulation of type I interferon signaling in immunity and inflammation: a comprehensive review","volume":"83","author":"Chen","year":"2017","journal-title":"J Autoimmun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1515\/hsz-2011-0260","article-title":"Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance","volume":"393","author":"Avgeris","year":"2012","journal-title":"Biol Chem"},{"key":"B55","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1096\/fj.03-1212fje","article-title":"Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease","volume":"18","author":"Blaber","year":"2004","journal-title":"FASEB J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/MNH.0b013e32834d54b1","article-title":"The kallikrein-kinin system and oxidative stress","volume":"21","author":"Kayashima","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B57","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fimmu.2012.00396","article-title":"The kallikrein-kinin system in experimental Chagas disease: a paradigm to investigate the impact of inflammatory edema on GPCR-mediated pathways of host cell invasion by Trypanosoma cruzi","volume":"3","author":"Scharfstein","year":"2012","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1189\/jlb.0106055","article-title":"Expression of kinin B1 and B2 receptors in immature, monocyte-derived dendritic cells and bradykinin-mediated increase in intracellular Ca2+ and cell migration","volume":"81","author":"Bertram","year":"2007","journal-title":"J Leukoc Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cellimm.2009.09.006","article-title":"The ACE inhibitors enalapril and captopril modulate cytokine responses in Balb\/c and C57Bl\/6 normal mice and increase CD4(+)CD103(+)CD25(negative) splenic T cell numbers","volume":"260","author":"Albuquerque","year":"2010","journal-title":"Cell Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nature03464","article-title":"IRF-7 is the master regulator of type-I interferon-dependent immune responses","volume":"434","author":"Honda","year":"2005","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/imm.12337","article-title":"Both plasmacytoid dendritic cells and monocytes stimulate natural killer cells early during human herpes simplex virus type 1 infections","volume":"143","author":"Vogel","year":"2014","journal-title":"Immunology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.semcdb.2008.08.010","article-title":"Inteferons pen the JAK-STAT pathway","volume":"19","author":"Schindler","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","article-title":"CXCL10 and autoimmune diseases","volume":"8","author":"Lee","year":"2009","journal-title":"Autoimmun Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4081\/reumatismo.2013.719","article-title":"Urinary CXCL10: a marker of nephritis in lupus patients","volume":"65","author":"Marie","year":"2013","journal-title":"Reumatismo"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1002\/art.20598","article-title":"Interferon-inducible protein 10\/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus","volume":"50","author":"Okamoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B66","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1165\/rcmb.2002-0040OC","article-title":"Bradykinin induces interleukin-6 production in human airway smooth muscle cells: modulation by Th2 cytokines and dexamethasone","volume":"28","author":"Huang","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1515\/BC.2010.042","article-title":"Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing","volume":"391","author":"Chao","year":"2010","journal-title":"Biol Chem"},{"key":"B68","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1523-1755.2004.00462.x","article-title":"An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis","volume":"65","author":"De Albuquerque","year":"2004","journal-title":"Kidney Int"},{"key":"B69","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/hrt.52.5.530","article-title":"Captopril in heart failure. A double blind controlled trial","volume":"52","author":"Cleland","year":"1984","journal-title":"Br Heart J"},{"key":"B70","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/hrt.72.1.63","article-title":"Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial","volume":"72","author":"Seneviratne","year":"1994","journal-title":"Br Heart J"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S0140-6736(84)91821-X","article-title":"Captopril: a new treatment for rheumatoid arthritis?","volume":"1","author":"Martin","year":"1984","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.advms.2017.06.004","article-title":"A systematic review on the role of eicosanoid pathways in rheumatoid arthritis","volume":"63","author":"Hoxha","year":"2017","journal-title":"Adv Med Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1101029","article-title":"Regulation of immune responses by prostaglandin E2","volume":"188","author":"Kalinski","year":"2012","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1152\/jappl.1995.78.2.623","article-title":"Production of PGE2 by bovine cultured airway smooth muscle cells: regulation by cAMP","volume":"78","author":"Barry","year":"1995","journal-title":"J Appl Physiol (1985)"},{"key":"B76","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4049\/jimmunol.159.1.28","article-title":"IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells","volume":"159","author":"Kalinski","year":"1997","journal-title":"J Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.4049\/jimmunol.1601073","article-title":"Prostaglandin E2 inhibition of IL-27 production in murine dendritic cells: a novel mechanism that involves IRF1","volume":"198","author":"Hooper","year":"2017","journal-title":"J Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.it.2015.02.002","article-title":"Dynamic control of type I IFN signalling by an integrated network of negative regulators","volume":"36","author":"Porritt","year":"2015","journal-title":"Trends Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00156\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T12:40:58Z","timestamp":1751287258000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00156\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2018.00156"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00156","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"article-number":"156"}}